-+ 0.00%
-+ 0.00%
-+ 0.00%

Takeda's BioLife Plasma Services Begins Introducing New Fresenius Kabi Adaptive Nomogram Across U.S. Network Of Plasma Donation Centers

Benzinga·05/05/2025 12:06:09
Listen to the news

-New Technology Optimizes Plasma Collection Resulting in Efficiency Gains

-Helps Strengthen Plasma Supply Used to Produce Lifesaving and Life-Sustaining Medicines

BioLife Plasma Services, part of Takeda (NYSE:TAK), today announced that it has begun introducing the new Fresenius Kabi Adaptive Nomogram across its U.S. network of plasma donation centers. The new Adaptive Nomogram is used on the Aurora Xi Plasmapheresis System, which is in more than half of BioLife's U.S. plasma donation centers. This new technology will be running in all BioLife donation centers using the Aurora Xi Plasmapheresis System by the end of December 2025.